FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088117868> ?p ?o ?g. }

• W3088117868 endingPage "6506" @default.
• W3088117868 startingPage "6497" @default.
• W3088117868 abstract "Background/Aims: Chemotherapy resistance of malignancies is a universal phenomenon which unfavorably affects therapeutic results. Genetic adaptations as well as epigenetic factors can play an important role in the development of multidrug resistance. Cytotoxic drug content in plasma of cancer patients is known to variate up to one hundred-fold regardless of the same dose injected per m2 body surface. The relationship between plasma concentrations, tissue uptake, and chemotherapy response is not completely understood. The main objective of this study was to investigate how the identical dose of Doxorubicin (Dox) can result in a different therapeutic response pattern depending on tumor size. Study Design: The study was performed on ascitic EL4 lymphoma in an exponential growth phase focusing on the rapidly changing tumor susceptibility to the Dox treatment. Well distinguishable tumor response patterns (curability, remission-relapse, resistance) were selected to unveil Dox intratumoral uptake and drug tissue persistence. Intratumoral Dox content within peritoneal cavity (PerC) in conjunction with systemic toxicity and plasma pharmacokinetics, were monitored at several time points following Dox injection in tumor bearing mice (TBM) with differing patterns of response. Results: Following intraperitoneal (i.p.) transplantation of 5x104 EL4 lymphoma cells rapid exponential proliferation with ascites volume and animal mass increase resulted in median survival of 14.5 days. The increase in tumor cell mass in PerC between day 3 and day 9 was 112.5-fold (0.2±0.03 mg vs 22.5±0.31 mg respectively). However, tumors at this time interval (day 3 to day 9 post-transplantation) were relatively small and constituted less than 0.05% of animal weight. An identical dose of Dox (15 mg/kg) injected intravenously (i.v.) on Day 3 lead to a cure whereas a TBM injected on day 9 exhibited resistance with a median survival time no different from the untreated TBM control. Injection of Dox resulted in noticeable differences of cellular uptake in PerC between all three groups of TBM (cure, relapse, resistance). Larger tumors were consistently taking up less Dox 60 min after the 15 mg/kg i.v. bolus injection. Higher initial uptake resulted also in longer retention of drug in PerC cells. The area under the concentration curve in PerC cells AUC0-10d was 8.2±0.57 µg/g x h, 4.6±0.27 µg/g x h and 1.6±0.02 µg/g x h in cure, relapse and resistance TBM respectively (p<0.05 relapse vs cure and p<0.001 resistance vs cure). No differences in plasma Dox pharmacokinetics or systemic hematological effects were observed in TBM following a single i.v. Dox push. Hematologic nadir was tested on day 2 and subsequent hematologic recovery was evaluated on day 10 following Dox administration. Hematologic recovery on day 10 coincided with complete drug efflux from PerC and rising tumor cell numbers in PerC of relapse TBM. Myelosuppression and hematological recovery patterns were identical in all surviving animal groups regardless of the tumor size on the day of Dox injection. Conclusions: Within a few days of exponential tumor growth, an identical dose of Dox produced dramatically different responses in the TBM with increasing resistance. Systemic toxicity and plasma pharmacokinetics were indistinguishable between all TBM groups. Initial uptake in tumor cells was found to be consistently lower in larger tumors. Drug uptake in tumor cells was regulated locally - a phenomenon known as inoculum effect in vitro. The duration of drug retention in cells was directly related to initial cellular uptake. The magnitude of Dox cellular retention could potentially play a role in determining tumor remission and relapse." @default.
• W3088117868 created "2020-10-01" @default.
• W3088117868 creator A5013242159 @default.
• W3088117868 creator A5020995946 @default.
• W3088117868 creator A5051018095 @default.
• W3088117868 creator A5062100615 @default.
• W3088117868 creator A5063105392 @default.
• W3088117868 creator A5072012380 @default.
• W3088117868 creator A5079116205 @default.
• W3088117868 creator A5085165502 @default.
• W3088117868 creator A5089413758 @default.
• W3088117868 creator A5021970878 @default.
• W3088117868 date "2020-01-01" @default.
• W3088117868 modified "2023-10-05" @default.
• W3088117868 title "Doxorubicin uptake in ascitic lymphoma model: resistance or curability is governed by tumor cell density and prolonged drug retention" @default.
• W3088117868 cites W1523876923 @default.
• W3088117868 cites W1532183186 @default.
• W3088117868 cites W1561977930 @default.
• W3088117868 cites W1569513357 @default.
• W3088117868 cites W1964613765 @default.
• W3088117868 cites W1971119720 @default.
• W3088117868 cites W1978107718 @default.
• W3088117868 cites W1999711678 @default.
• W3088117868 cites W2007072692 @default.
• W3088117868 cites W2009980816 @default.
• W3088117868 cites W2017908039 @default.
• W3088117868 cites W2037780445 @default.
• W3088117868 cites W2043424991 @default.
• W3088117868 cites W2048556470 @default.
• W3088117868 cites W2050287786 @default.
• W3088117868 cites W2056551122 @default.
• W3088117868 cites W2064973797 @default.
• W3088117868 cites W2067462298 @default.
• W3088117868 cites W2077361516 @default.
• W3088117868 cites W2087711359 @default.
• W3088117868 cites W2089357150 @default.
• W3088117868 cites W2090328782 @default.
• W3088117868 cites W2094187708 @default.
• W3088117868 cites W2112260434 @default.
• W3088117868 cites W2128560067 @default.
• W3088117868 cites W2133475948 @default.
• W3088117868 cites W2137009835 @default.
• W3088117868 cites W2142874979 @default.
• W3088117868 cites W2149160937 @default.
• W3088117868 cites W2157393167 @default.
• W3088117868 cites W2157950889 @default.
• W3088117868 cites W2171393903 @default.
• W3088117868 cites W2409090678 @default.
• W3088117868 cites W2417282402 @default.
• W3088117868 cites W2562238960 @default.
• W3088117868 cites W2767934734 @default.
• W3088117868 cites W2787777316 @default.
• W3088117868 cites W2810338268 @default.
• W3088117868 cites W2908270033 @default.
• W3088117868 cites W2948517706 @default.
• W3088117868 cites W2953658820 @default.
• W3088117868 cites W2985709197 @default.
• W3088117868 cites W2995956442 @default.
• W3088117868 cites W31750938 @default.
• W3088117868 cites W1846815971 @default.
• W3088117868 doi "https://doi.org/10.7150/jca.46066" @default.
• W3088117868 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7545667" @default.
• W3088117868 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33046971" @default.
• W3088117868 hasPublicationYear "2020" @default.
• W3088117868 type Work @default.
• W3088117868 sameAs 3088117868 @default.
• W3088117868 citedByCount "4" @default.
• W3088117868 countsByYear W30881178682021 @default.
• W3088117868 countsByYear W30881178682022 @default.
• W3088117868 countsByYear W30881178682023 @default.
• W3088117868 crossrefType "journal-article" @default.
• W3088117868 hasAuthorship W3088117868A5013242159 @default.
• W3088117868 hasAuthorship W3088117868A5020995946 @default.
• W3088117868 hasAuthorship W3088117868A5021970878 @default.
• W3088117868 hasAuthorship W3088117868A5051018095 @default.
• W3088117868 hasAuthorship W3088117868A5062100615 @default.
• W3088117868 hasAuthorship W3088117868A5063105392 @default.
• W3088117868 hasAuthorship W3088117868A5072012380 @default.
• W3088117868 hasAuthorship W3088117868A5079116205 @default.
• W3088117868 hasAuthorship W3088117868A5085165502 @default.
• W3088117868 hasAuthorship W3088117868A5089413758 @default.
• W3088117868 hasBestOaLocation W30881178681 @default.
• W3088117868 hasConcept C112705442 @default.
• W3088117868 hasConcept C114851261 @default.
• W3088117868 hasConcept C121608353 @default.
• W3088117868 hasConcept C126322002 @default.
• W3088117868 hasConcept C143998085 @default.
• W3088117868 hasConcept C2776694085 @default.
• W3088117868 hasConcept C2779338263 @default.
• W3088117868 hasConcept C2780496750 @default.
• W3088117868 hasConcept C2781303535 @default.
• W3088117868 hasConcept C2911091166 @default.
• W3088117868 hasConcept C502942594 @default.
• W3088117868 hasConcept C71924100 @default.
• W3088117868 hasConcept C86803240 @default.
• W3088117868 hasConcept C89423630 @default.
• W3088117868 hasConcept C98274493 @default.
• W3088117868 hasConceptScore W3088117868C112705442 @default.

• next